Eagle Pharmaceuticals, Inc.
EGRX · OTC
3/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$2,666 | $35,642 | -$8,627 | $11,989 |
| Dep. & Amort. | $16,668 | $12,024 | $3,760 | $4,766 |
| Deferred Tax | $29,931 | -$8,324 | -$3,618 | -$1,511 |
| Stock-Based Comp. | $0 | $16,451 | $19,555 | $24,756 |
| Change in WC | $866 | -$16,404 | $9,537 | $816 |
| Other Non-Cash | -$14,002 | $11,312 | $7,612 | $8,681 |
| Operating Cash Flow | $30,797 | $50,701 | $28,219 | $49,497 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | $0 | -$178 | -$323 | -$747 |
| Net Acquisitions | $0 | -$74,152 | $0 | $0 |
| Inv. Purchases | $0 | -$12,500 | $0 | -$17,500 |
| Inv. Sales/Matur. | $0 | $74,152 | $0 | $0 |
| Other Inv. Act. | $0 | -$74,152 | -$5,000 | $0 |
| Investing Cash Flow | $0 | -$86,830 | -$5,323 | -$18,247 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $12,764 | -$8,000 | -$5,000 |
| Stock Issued | $0 | $0 | $0 | $0 |
| Stock Repurch. | $0 | -$18,004 | -$21,213 | -$34,999 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $0 | -$969 | $821 | $2,129 |
| Financing Cash Flow | $0 | -$6,209 | -$28,392 | -$37,870 |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Chg. in Cash | $30,797 | -$42,338 | -$5,496 | -$6,620 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $55,321 | $97,659 | $103,155 | $109,775 |
| End Cash | $30,797 | $55,321 | $97,659 | $103,155 |
| Free Cash Flow | $30,797 | $50,523 | $27,896 | $48,750 |